CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D064420: Drug-Related Side Effects and Adverse Reactions NIH

(Synonyms: Drug-Related Side Eff, Drug-Related Side Effect, Drug-Related Side Effects and Adver, Drug-Related Side Effects and Adverse R, Drug-Related Side Effects and Adverse Reactions)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2631 Simulation of Repurposed Drugs for COVID-19 Wiki 0.71

Correlated MeSH Terms (0)


Name (Synonyms) Correlation

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy

This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled in PACE organizations. Our clinical tool would enable to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ADE) developing in elderly patients infected with COVID-19.

NCT04339634 COVID Drug Effect Drug Interaction Adverse Drug Event Other: Simulation of Repurposed Drugs for COVID-19
MeSH:Drug-Related Side Effects and Adverse Reactions

Primary Outcomes

Description: Quantitative

Measure: To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.

Time: Three months

Description: Quantitative

Measure: To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.

Time: Three months

Description: Quantitative

Measure: To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.

Time: Three months

Description: Quantitative

Measure: To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.

Time: 3 months

Secondary Outcomes

Description: Qualitative

Measure: To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19.

Time: 6 months

Description: Qualitative

Measure: To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used.

Time: 1 year

2 Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations

This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in a health insurance population. Our clinical tool would enable us to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ADE) developing in these patients infected with COVID-19.

NCT04378881 COVID Drug Effect Drug Interaction Adverse Drug Event
MeSH:Drug-Related Side Effects and Adverse Reactions

Primary Outcomes

Description: Quantitative

Measure: Calculate the Medication Risk Score of de-identified participants from Medicare/Medicaid and commercial health insurance plans using their current drug regimen via our proprietary risk stratification process.

Time: Three months

Description: Quantitative

Measure: Simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen via our proprietary risk stratification process.

Time: Three months

Description: Quantitative

Measure: Compare the impact (change) on the Medication Risk Score using the calculate before score and simulated after score following the addition of repurposed drugs for COVID-19 to the drug regimens of patients enrolled in the study.

Time: Three months

Description: Quantitative

Measure: Measure the effects of various repurposed drugs for COVID-19 on each of the five factors computed by algorithms to derive the Medication Risk Score will be calculated via our proprietary risk stratification process.

Time: Three months

Secondary Outcomes

Description: Qualitative

Measure: Comparison of the Medication Risk Score and the effects of the addition of repurposed drugs on the drug regimen between participants with Medicare/Medicaid vs. commercial health insurance plans will be assessed.

Time: Six months

Description: Qualitative

Measure: Measure the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used and the impact of various covariables.

Time: One year


HPO Nodes